Literature DB >> 8301625

Does a highly diluted homoeopathic drug act as a placebo in healthy volunteers? Experimental study of Belladonna 30C in double-blind crossover design--a pilot study.

H Walach1.   

Abstract

A basic tenet of homoeopathy is that remedies which do not contain active molecules can have effects on the healthy human organism, by virtue of the specific preparation process of stepwise dilution and succussion, called potentization. The claim that a so called high 'potency' of a homoepathic remedy, Belladonna C30, could produce effects different from placebo, was investigated in a pilot study. In a double-blind crossover trial, 4 weeks of Belladonna C30 were compared to 4 weeks of placebo in 47 healthy volunteers. Data were collected daily. The number and types of changes were recorded into a predefined category system. Single-case evaluation showed differences between the two experimental phases for 21 subjects. Group evaluation showed no clearcut differences. The claim that homoeopathic potencies can produce symptoms other than placebo in healthy subjects should be put to further scrutiny.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8301625     DOI: 10.1016/0022-3999(93)90174-e

Source DB:  PubMed          Journal:  J Psychosom Res        ISSN: 0022-3999            Impact factor:   3.006


  4 in total

1.  The debate over complementary medicine continues. Evidence for homoeopathy is lacking.

Authors:  D Ramey
Journal:  BMJ       Date:  2000-05-13

2.  Randomized double-blind placebo-controlled trial of homoeopathic 'proving' for Belladonna C30.

Authors:  K Goodyear; G Lewith; J L Low
Journal:  J R Soc Med       Date:  1998-11       Impact factor: 5.344

3.  Ultramolecular homeopathy has no observable clinical effects. A randomized, double-blind, placebo-controlled proving trial of Belladonna 30C.

Authors:  Sarah Brien; George Lewith; Trevor Bryant
Journal:  Br J Clin Pharmacol       Date:  2003-11       Impact factor: 4.335

4.  The conclusion that 'ultramolecular homeopathy has no observable clinical effects' is not supported by the data.

Authors:  Edward Shalts; Samuel Shiflett
Journal:  Br J Clin Pharmacol       Date:  2004-09       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.